A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer
NCT07401381
This study is recruiting at 3 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The study aims to compare the amount of the drug letrozole that gets into the bloodstream after multiple doses of the quarterly injection Letrozole SIE, versus multiple doses of the standard oral daily tablet of letrozole (Femara®), in women who have gone through menopause and have received treatment for hormone receptor-positive early breast cancer. Participants must have completed at least five years of hormone therapy with at least two of those years with letrozole before starting their participation in the study.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Hormone Receptor Positive Early Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 80 years
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- Rovi Pharmaceuticals Laboratories
- Last updated on ClinicalTrials.gov
- October 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Precision NextGen Oncology and Research Center (Investigational Site number USA-001) · Beverly Hills, CA
Florida · 2
- D&H National Research Centers INC (Investigational Site number USA-002) · Margate, FL
- United Medical Research (Investigational Site number USA-005) · Port Orange, FL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.